Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Hepatocellular Carcinoma
Clinical trial register · China

Hepatocellular Carcinoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 07 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Guangzhou 12 Beijing 6 Guanzhou 1 Changsha 1
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou12 Beijing6 Guanzhou1 Changsha1
All 4 locations
Target enrolment
to

Hepatocellular Carcinoma trials in China

20 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
NCT07324824Hepatocellular Carcinoma, Neoadjuvant Therapy, Sintilimab, Bevacizimab
Sun Yat-sen University
Phase 2
37
Guangzhou
2026-01-14
Recruiting
TACE Combined Surgery for the Resectable Huge HCC
NCT06898398Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer, Surgery
Sun Yat-sen University
Observational
326
Beijing
2025-01-01
Recruiting
Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
NCT06446154Hepatocellular Carcinoma, Immune Checkpoint Inhibitors, Anti-angiogenic Therapy, Second-line Treatment
Sun Yat-sen University
Phase 2
36
Guangzhou
2024-12-27
Recruiting
TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma
NCT06740370Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Anti-PD1 Antibody, Lenvatinib
Sun Yat-sen University
Not applicable
32
Beijing
2024-12-13
Recruiting
HAIC Compared With TACE in Huge Hepatocellular Carcinoma
NCT06641713Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer
Sun Yat-sen University
Observational
664
Beijing
2024-10-01
Recruiting
TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
NCT06622031Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Systemic Therapy
Sun Yat-sen University
Not applicable
42
Beijing
2024-10-01
Recruiting
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
NCT06609876Hepatocellular Carcinoma, Microwave Ablation, Donafenib, Recurrent Tumor
Sun Yat-sen University
Not applicable
108
Beijing
2024-10-01
Recruiting
Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC
NCT06467799Hepatocellular Carcinoma, Beyond Milan Criteria
Sun Yat-sen University
Phase 2
39
Guangzhou
2024-09-01
Recruiting
Sun Yat-sen University
Phase 2
140
Guangzhou
2024-04-05
Recruiting
Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
NCT06265350Hepatocellular Carcinoma, Liver Cancer Stage IV, Pulmonary Metastases, Cadonilimab
Sun Yat-sen University
Not applicable
80
Guanzhou
2024-02-02
Recruiting
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
NCT06041477Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity
Sun Yat-sen University
Phase 3
540
Guangzhou
2023-10-31
Recruiting
Sun Yat-sen University
Phase 2
43
Guangzhou
2023-09-01
Recruiting
Sun Yat-sen University
Phase 2
55
Guangzhou
2023-03-09
Recruiting
Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
NCT05444478Hepatocellular Carcinoma, Microwave Ablation, Liver Cancer, Lenvatinib
Sun Yat-sen University
Not applicable
274
Changsha
2022-07-01
Active, closed
Sun Yat-sen University
Phase 3
214
Guangzhou
2022-01-17
Recruiting
Sun Yat-sen University
Not applicable
320
Guangzhou
2021-02-20
Recruiting
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
NCT06333561Hepatocellular Carcinoma, Lenvatinib, PD-1 Inhibitor, Hepatic Arterial Infusion Chemotherapy
Sun Yat-sen University
Observational
300
Beijing
2021-01-01
Active, closed
Sun Yat-sen University
Phase 2
40
Guangzhou
2019-03-25
Rows per page Showing 1–20 of 20
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 November 2026. https://priyalifescience.com/clinical-trials-china/condition/hepatocellular-carcinoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 07 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 20 of those studies listing the condition Hepatocellular Carcinoma that also match the filters currently applied.

How many Hepatocellular Carcinoma trials are recruiting in China?

18 of the 20 studies on this page are recruiting new participants as of the 07 Nov 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hepatocellular Carcinoma), 20 studies
PhaseStudiesRecruitingShare
Phase 27635%
Not applicable6630%
Phase 34320%
Observational3315%

Most active sponsors

Lead sponsors with the most studies (Hepatocellular Carcinoma)
Lead sponsorStudiesRecruiting
Sun Yat-sen University2018
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.